Stryker Corporation vs Toro Company (The) Common Stock — how do they compare? Stryker Corporation trades at $285 (market cap $108.02B), while Toro Company (The) Common Stock trades at $98.27 (market cap $9.30B). The key difference: Stryker Corporation is far larger — about 11.6× Toro Company (The) Common Stock's market cap, and Toro Company (The) Common Stock pays the higher dividend (1.59%). Which is the better fit depends on your goals — on Pluang, investors hold Stryker Corporation for 22 Days and Toro Company (The) Common Stock for 0 Days on average.
| SYK | TTC | |
|---|---|---|
Market Cap | $108.02B | $9.30B |
Volume | 2,222,698 | 420,909 |
Sector | Health | Industrials |
52-Week High | $388.35 | $101.76 |
52-Week Low | $269.75 | $67.99 |
Typical Hold Time | 22 Days | 0 Days |
Enterprise Value | $119.49B | $10.20B |
Dividend Yield | 1.25% | 1.59% |
Signals from Pluang's Aura AI — not financial advice
Stryker (SYK) trades at $282.63, showing minimal daily movement. The stock exhibits a neutral technical stance with mixed moving averages and oscillators. Fundamentally, SYK maintains strong profitability with a 14.43% net income margin and 16.51% ROE, though a P/E of 29.28 suggests a premium valuation. Recent news highlights ongoing legal scrutiny over a manufacturing issue disclosed in September 2026, which caused a significant price drop. Q3 2026 earnings are anticipated on October 29, 2026, following a mix of beats and misses in prior quarters.
The outlook for SYK is cautiously optimistic, supported by analyst consensus with a $365.89 price target and no sell ratings. Investment appeal lies in its solid cash flow and market position, but risks include legal investigations and persistent operational challenges. The stock's near-term direction will likely hinge on Q3 earnings results and clarity on the manufacturing issue resolution.
Toro Company (TTC) trades at $97.88, up 1.27% with strong technical momentum above its 50-day moving average. The company demonstrates solid fundamentals with consistent earnings beats, including Q2 2026 EPS of $1.33 beating expectations of $1.31, and raised full-year guidance. Revenue growth of 8.4% in Q3 2026 to $1.23 billion reflects robust demand across professional and residential segments, supported by infrastructure and automation initiatives under new CEO leadership.
Toro presents a balanced investment case with 36% analyst buy ratings and $117.50 price target suggesting 20% upside. However, execution risks from inflation, tariffs, and competitive pressures warrant caution. The stock's premium valuation (P/E 26.17) requires sustained earnings growth, making Q3 2026 results critical for validating current momentum.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →The Toro Company designs, manufactures, and markets equipment for turf maintenance, snow and ice management, landscaping, construction, and irrigation. Its products serve golf courses, sports fields, and residential and commercial properties in more than 125 countries.
Read more on TTC →